Editas Medicine and MaxCyte Announce Clinical and Commercial License Agreement for Engineered Cell Medicines

NEXT STORY
ADMA Biologics Announces Data Presented at IDWeek 2019
PREV STORY
BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

NewLink Genetics Announces Presentation of Abstracts at AACR Annual Meeting

AMES, Iowa, March 14, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today reported ...

author_avatar
NASDAQ Market News

University of Miami Health System and One Medical Announce Affiliation Focused on Seamless Coordinated Care

author_avatar
NASDAQ Market News

Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne

DUBLIN, Ireland and BOSTON, March 27, 2017 (GLOBE NEWSWIRE) -- Allergan plc, (NYSE:AGN), a ...

author_avatar
NASDAQ Market News